Axogen Inc (AXGN)vsBoston Scientific Corp (BSX)
AXGN
Axogen Inc
$42.80
+0.97%
HEALTHCARE · Cap: $2.10B
BSX
Boston Scientific Corp
$48.55
-0.32%
HEALTHCARE · Cap: $70.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 8558% more annual revenue ($20.61B vs $238.10M). BSX leads profitability with a 17.3% profit margin vs -13.2%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
AXGN
Avoid30
out of 100
Grade: F
BSX
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AXGN.
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 26.6% year-over-year
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Areas to Watch
Trading at 9.3x book value
0.0% earnings growth
Weak financial health signals
Expensive relative to growth rate
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : AXGN
The strongest argument for AXGN centers on Debt/Equity, Revenue Growth. Revenue growth of 26.6% demonstrates continued momentum.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : AXGN
The primary concerns for AXGN are Price/Book, EPS Growth, Piotroski F-Score.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Key Dynamics to Monitor
AXGN profiles as a growth stock while BSX is a mature play — different risk/reward profiles.
AXGN carries more volatility with a beta of 1.17 — expect wider price swings.
AXGN is growing revenue faster at 26.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 30/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axogen Inc
HEALTHCARE · MEDICAL DEVICES · USA
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?